

Thank you for choosing AXIA!

AXIA Pharmaceutical is an FDA-registered outsourcing facility that works closely with universities, physicians, clinics, and hospitals to create high-quality injectable medications for a variety of markets. With past clients, we have developed a contract manufacturing program that leverages agility with cost. Our state-of-the-art facility contains all the modern technology necessary to provide our clients with pure injectable pharmaceutical agents of the highest quality. Our devotion to providing the highest quality sterile injectable medications and analytical work available in the industry is supported by implementation of

- a cGMP/cGLP facility;
- FDA registration and a DEA license;
- fully validated sterilization procedures;
- a strong aseptic training program and validated media fill processes;
- superior gowning processes and environmental monitoring;
- cutting-edge ScanRDI and BacTAlert sterility testing;
- a state-of-the-art Cleanroom facility with cleaning and disinfection procedures and material segregation;
- routine equipment calibrations to assure proper performance;
- full documentation and recording of materials handling for accountability;
- class-leading Quality Assurance and Control systems to ensure that all our products are completely sterile and safe before distribution to the client.
- our Proactive Production Planning Program (P⁴) to support rapid turnaround times and avoid needing to make costly last-minute changes that lead to delays and expenses.

Thank you for taking the time to fill out the following information, which helps us to maintain compliance with the regulatory hodies to whose high standards we meet. We appreciate the

compliance with the regulatory bodies to whose	ingn standards we meet.	we appreciate the
opportunity to act as your Outsourcing Facility.	We look forward to hearin	g from you and to
counting you amongst our many satisfied client	:s!	

Thank you,

Your AXIA Team

Rev: 07APR2018



Medical/Clinical Necessity Form

POLICY: It is the policy of FusionIV Pharmaceuticals dba AXIA Pharmaceutical to conduct its business in compliance with applicable federal, state and local laws and regulations, and to adhere to the highest ethical standards.

STANDARD: It is the standard of FusionIV Pharmaceuticals dba AXIA Pharmaceutical to provide only manufactured sterile injectable products which are not essentially copies of one or more approved drugs. However, there are cases in which drugs are determined to be medically/clinically necessary which may seem to be in conflict with this policy. "Medically/clinically necessary" is defined as:

- Consistent with generally-accepted standards in the field of treatment, or other discrete clinical discipline, providing a designated effect;
- Are reasonable and necessary to protect life, to prevent significant illness or significant disability, or to alleviate severe pain;
- Are appropriate to the condition or need set being treated;
- Require the specific level of care or expertise being proposed;
- Are individualized based on the assessed needs of the individual;
- Are provided in the most integrated setting for the given need(s) being addressed;
- Are not conducted for the convenience of the provider, the person receiving the service, family members, payers, or any other parties.

Manufactured sterile injectable products that are "medically/clinically necessary" may be required when:

- Best practice clinical intervention has not been effective;
- Differential diagnosis is indicated to develop a more effective treatment plan;
- The individual has a medical or neurological condition and has been referred by a physician for further assessment after being evaluated by the MD;
- An individual presents with concerns regarding specialized services.

Such products manufactured by FusionIV Pharmaceuticals dba AXIA Pharmaceutical cannot be billed to insurance using an NDC for a similar product produced by any other entity. FusionIV Pharmaceuticals dba AXIA Pharmaceutical will not be held liable for issues arising from how products are billed.

Reason for being medically/clinically necessary (please check	all that apply):				
☐ Change in administration					
☐ Change in strength					
☐ Addition/removal of excipient					
☐ Is on FDA Drug Shortage list					
☐ Is not otherwise available or cannot be easily obtained through other means					
□ other (specify):					
My signature on this document signifies that as of	(date), I,				
, hereby certify that the produ	cts(s) requested is/are medically and/or				
clinically necessary despite being related to one or more approved drugs, and I do not hold FusionIV					
Pharmaceuticals dba AXIA Pharmaceutical responsible for any matters related to its/their billing.					



Physician Account Agreement

1990 Westwood Blvd Suite 135 Los Angeles, CA 90025 Tel: 877. 685.8222 Fax: 866.732.4194

	ew Customer	□Chang	e of Owners	hip	☐ Changes to	Existing Acct
Business Contact Information						
Title:						
Practice	e Name:					
Phone:		Fax:	E-	-mail:		
Shippin	g Address:					
City:			State:		Zip Code:	
Federal	Tax ld or SS	# :				
Please	provide Licen	ıse. DEA. a	nd NPI Num	bers	for All prescril	bing Physicians
	Name	, ,	License		DEA	NPI
	any delays in cial shipping ir		•	us w	rith your busin	ess hours and
	Office Hours:					
Special Shipping Instructions						



Physician Account Agreement

By signing below you agree to pay any and all amounts charged by FusionIV Pharmaceutical d/b/a AXIA Pharmaceuticals to your credit card account specified below, and authorize FusionIV Pharmaceuticals d/b/a AXIA Pharmaceutical to obtain credit approval from said credit card company.

I hereby authorize FusionIV Pharmaceuticals d/b/a AXIA Pharmaceutical to charge my credit card account specified below. I affirm that I am at least 18 years old and that I am legally authorized to use the credit card account number specified below.

Furthermore I understand and agree that any charges made to the account specified below are nonrefundable, and I agree to pay FusionIV Pharmaceuticals d/b/a AXIA Pharmaceutical pursuant to my agreement with said credit card company, any such amounts charged by me both in the past and henceforth. Additionally I agree to hold FusionIV Pharmaceuticals d/b/a AXIA Pharmaceutical fully harmless from and against all claims whatsoever resulting from any charges made to said credit card billed to the credit card shown below.

Signature	Date		
Printed Name	Title		
Credit Ca	ard Information		
Name:	Credit Card #		
Exp Date:	Billing Zip Code:		
Security Code:			
Billing Address:			
.	.01 for card verification. If the transaction is		
declined, you will be contacted to update	the credit card information before your		
application is accepted.			
Does your office sell controlled s	ubstances?		
□Yes □No			



Company:		DEA#/Exp:			
Contact:		Email:			
Address:		City, State, Zip:			
Telephone:		Fax:			
substances, AXI	ustomer: In order to comply with 21 CFI A identifies and establishes the authoriza ance and only accepts such orders from p	tion status of each p	person seeking to order a		
authorized personne	All personal information obtained for this purpose el and secured to maintain the privacy of your person, but must be disclosed to law enforcement person	onal information. This is	nformation will not be disseminated		
Authorized Pur	rchasing Agent: (Print)				
Title:	Authorized to Purchase (Specify Schedules): N/A				
Agent Signature	:	Date:			
Check ONE:					
☐ This practice	does not use Controlled Substances but is	s aware of the polic	ies herein.		
hereby authorize	ed by the above registrant to designate the the above person to purchase the specificitrant. This authorization shall include Dec.	ed schedules of con	trolled substances in behalf		
registrant's mos execute Order F	ders Only: The person designated above t recent DEA registration, or holds curren orms (Forms 222) for Schedule II on beh Date:	tly-valid Power of	Attorney from that person to		
Purchasing Co	mpany Official:				
Name:		Title:			
Signature:		Date:			



DEAR CUSTOMER: The DEA has increased its surveillance and scrutiny of manufacturers, wholesalers, and distributors of controlled substances as a matter of public safety to ensure that such items are not diverted or misused. Furthermore, recently enacted legislation places greater responsibility on pharmacies to prevent the illegal distribution and dispensing of controlled substances via online sites. One of the main factors contributing to the nationwide increase in diversion of pharmaceutical controlled substances has been the rise in the number of online sites that sell or facilitate the sale of these drugs for illicit purposes. AXIA requires its customers to complete this three-part form. It ensures customers' orders can be promptly filled. It also is part of AXIA's compliance program to assure that controlled substances will be used for legitimate medical purposes. We thank you for your participation in this joint effort to protect the public safety by preventing diversion of controlled substances.

PART ONE - BUSINESS INFORMATION

Company:			DEA # / Exp.:			
Contact:			Email:			
Address:			City,	State, Zip:		
Telephone:			Fax:			
1.1 Please se to your praction	lect all that apply ce:	□ Independent □ Pain Manage	ement	Clinic Veterinal	rian	□ Hospital □ University
1.2 Approximately what percentage of your practice's business involves dispensing controlled substances?				;		
1.3 Does your practice ship controlled substances to other states?					YES 🗖 NO 🗖	
1.4 If your response to question 1.3 above is "Yes," is your practice in compliance with the controlled substance laws of the other states to which you ship controlled substances?				ich	YES NO	
1.5 Has any previous registration under the Controlled Substances Act (state or federal) held by any officer or owner ever been surrendered, revoked, suspended, denied or is pending such action? If "yes," please attach a letter explaining the circumstances of such action.					YES NO	
1.6 Have any of the officers, owners or pharmacists ever been convicted of a felony or misdemeanor under state or federal law relating to the manufacture, distribution, or dispensing of controlled substances? If "yes," please attach a letter explaining the circumstances of such action.					d	YES D NO D



PART TWO - ONLINE PRACTICE INFORMATION

Notice of New DEA Regulations: As a valued AXIA customer, please be aware of newly enacted federal legislation that may affect your current DEA registration. The Ryan Haight Online Practice Consumer Protection Act (Ryan Haight Act), which became effective April 13, 2009, amended the Controlled Substances Act by adding new provisions to prevent the illegal distribution and dispensing of controlled substances via the Internet. The new law was symbolically named in memory of a teenager who died from a drug overdose after obtaining controlled substances online without a valid prescription.

Definition of an Online Practice: The Ryan Haight Act defines an online practice as a person, entity, or Internet site in the U.S. or abroad that knowingly or intentionally delivers, distributes, or dispenses a controlled substance via the Internet, and includes, among other things:

- Any Web site (sic) that sells, or offers to sell, any controlled substance or a prescription to a person in the United States.
- Any person who pays a practitioner to write prescriptions for controlled substances for customers of such a Web site (sic).
- Any person who pays a practice to fill prescriptions for controlled substances that were issued to customers of such a Web site (sic).
- Any practice that knowingly or intentionally fills prescriptions for controlled substances that were issued to customers of a Web site (sic).

What you must do: Most practices are not affected by the new registration requirements. However, every practice must determine whether the provisions of the Ryan Haight Act apply to its business and, if so, must obtain a modification of its DEA registration in order to continue delivering, dispensing, or distributing controlled substances via the Internet. A complete copy of the Ryan Haight Act is available online from the DEA Office of Diversion Control Website at:http://www.deadiversion.usdoj.gov/fed_regs/rules/2009/fr0406.pdf

2.1 Are you aware of the provisions of the Ryan Haight Act, and how they may apply to your practice?	YES 🗖	NO 🗖
2.2 Is your practice classified as an online practice as defined by the Ryan Haight Act?	YES 🗖	NO 🗖
2.3 If you responded "YES" to question 2.2 above, has your practice obtained a modified registration from DEA authorizing Online dispensing of controlled substances? If "yes," please attach a letter explaining the circumstances of such action.	YES 🗖	NO 🗖

COMPANY OFFICIAL (Owner, Officer, Pharmacist):

I make these representations for the purpose of obtaining controlled substances. I certify all the information I have provided is true, complete, and correct, and that the business named above operates in compliance with all applicable federal and state regulations. I further certify I am authorized to make these representations on behalf of the organization named above.

Name:	Title:	
Signature:	Date:	



PART THREE - PRODUCT USAGE INFORMATION:

[Please use a separate PART 3 for each controlled substance]

NOTE: Under 21 CFR 1301.74, AXIA is required to screen each controlled substance order for significant changes in quantities and ordering patterns. AXIA will use the requested information in Part Three to establish purchasing and use profiles for controlled substances. Information previously submitted to AXIA in response to Parts One and Two of the Controlled Substance Questionnaire remains valid for one year from the date of order acceptance. Customers need to complete and submit only Part Three of the Controlled Substance Order Questionnaire for additional orders of controlled substances placed during the one-year period of validity.

ne Controlled Substance Questionnaire remains valid for one year from the date of order acceptance. Customers leed to complete and submit only Part Three of the Controlled Substance Order Questionnaire for additional orders of controlled substances placed during the one-year period of validity.				
3.1 Product Des	cription:			
3.2 Catalog Num	nber:			
3.3 Size:				
3.4 Quantity:				
3.5 Dosage form	1:			
3.6 What is the r a) prescriptions us	number of sing this material per month?			
b) grams of mater	ial used per month?			
AXIA? YES 🗖	der represent a significant increase from past p NO □ attach a letter explaining the need for addit			
3.8 Have you pu	rchased this material from other suppliers? YE	S NO D		
3.9 If you answered YES to 3.8 above, what was your estimated usage of this material from all suppliers n the past six months?				
COMPANY OFFICIAL (Owner, Officer, Pharmacist): I make these representations for the purpose of obtaining controlled substances. I certify all the information I have provided is true, complete, and correct, and that the business named above operates in compliance with all applicable federal and state regulations. I further certify I am authorized to make these representations on behalf of the organization named above.				
Name:		Title:		
Signature:		Date:		



Shipping Policy

Thank you for choosing AXIA. Below are the terms and conditions that constitute our Shipping Policy.

Shipment Processing Time

Orders are generally processed within 1-2 business days.

Note: To ensure orders are processed the same day, the order must be received by 12 pm PST.

Shipping Rates & Delivery Estimates

To ensure the quality of our products is not compromised, all orders are shipped via overnight delivery.

Shipment Method	Estimated delivery time	Shipment cost
Standard Overnight (Non Refrigerated Items)	1-2 business days	\$20.00
Standard Overnight (Refrigerated Items)	1-2 business days	\$25.00

<u>Missed Deliveries:</u> Should your facility not be able to accept a scheduled delivery, the following charges will apply:

Refrigerated Items

Due to strict FDA regulations, all refrigerated items returned to our facility must be discarded and reprocessed. Customers will be billed **50%** of the order cost for replacement orders, along with standard shipping rates.

Non Refrigerated Items

All items returned to our facility due to non-delivery will be reshipped at the customer's expense.

Return Policy: No returns will be accepted for medication.

Name:	Title:	
Signature:	Date:	